• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Article

Remicade does well in study on inflammation

Washington, D.C. - In a recent 10-week, three-dose phase II trial of inflaximab (Remicade), 87.9 percent of the 250 participants achieved PASI 75, while 58 percent achieved PASI 90 at the 10-week mark.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe Now!
Related Videos
1 expert in this video
1 expert in this video
Related Content
FDA Approves Arcutis’ Roflumilast Foam for Plaque Psoriasis
May 22nd 2025

FDA Approves Arcutis’ Roflumilast Foam for Plaque Psoriasis

Derm Dispatch: Discussing Early Detection and Education With a Melanoma Survivor
May 20th 2025

Derm Dispatch: Discussing Early Detection and Education With a Melanoma Survivor

Real-World Data on the Adverse Effects of Apremilast and Deucravacitinib for Psoriasis
May 22nd 2025

Real-World Data on the Adverse Effects of Apremilast and Deucravacitinib for Psoriasis

Derm Dispatch: A Comprehensive Guide to Managing Eczema with Integrative Medicine
March 31st 2025

Derm Dispatch: A Comprehensive Guide to Managing Eczema with Integrative Medicine

Cutibacterium acnes Dominates the Post-Laser Skin Microbiome
May 22nd 2025

Cutibacterium acnes Dominates the Post-Laser Skin Microbiome

Daily Derm Times: May 21, 2025
May 22nd 2025

Daily Derm Times: May 21, 2025

© 2025 MJH Life Sciences

All rights reserved.